Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the "Shanghai Junshi Biosciences Co., Ltd.* Announcement on the Convening of the 2025 Interim Results Briefing" published by Shanghai Junshi Biosciences Co., Ltd.* on the website of the Shanghai Stock Exchange, for reference purpose only.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 29 August 2025

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive directors; Mr. Tang Yi as a non-executive director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Dr. Yang Yue, Mr. Li Zhongxian and Ms. Lu Kun as independent non-executive directors.

* *For identification purposes only*

Stock code: 688180 Stock Abbreviation: Junshi Bio Announcement No.: Lin 2025-043

Shanghai Junshi Biosciences Co., Ltd.*
Announcement on the Convening of the 2025 Interim Results Briefing

The board of directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

Important Notice:

- Time of the briefing: 10:00-11:00, 8 September 2025 (Monday)
- Venue of the briefing: Shanghai Stock Exchange Roadshow Center (https://roadshow.sseinfo.com/)
- Mode of the briefing: SSE Roadshow Center online interaction
- Investors are invited to ask questions through the "Pre-collection of Questions" section at the homepage of the SSE Roadshow Center website or send questions to the email of Shanghai Junshi Biosciences Co., Ltd.* (the "Company") (info@junshipharma.com) in advance from 1 September 2025 (Monday) to 16:00, 5 September 2025 (Friday). The Company will respond to questions that are of general concern to investors at the briefing.

The Company has disclosed its 2025 interim report on the website of the Shanghai Stock Exchange (www.sse.com.cn) on 27 August 2025. In order to facilitate investors to have a more comprehensive and in-depth understanding of the operating results and financial status of the Company for first half of 2025, the Company plans to convene the 2025 interim results briefing at 10:00-11:00, 8 September 2025, and communicate with investors about their concerns.

I. Type of the Briefing

This investor briefing will be held in the form of online interaction. The Company will interact and communicate with investors with regard to the operating results and financial indicators for first half of 2025. Questions that are of general concern to investors will be answered subject to restrictions under the information disclosure rules.

II. Time and Venue of the Briefing

(I) Time of the briefing: 10:00-11:00, 8 September 2025 (Monday)

(II) Venue of the briefing: SSE Roadshow Center (https://roadshow.sseinfo.com/)

(III) Mode of the briefing: SSE Roadshow Center online interaction

III. Attendees

Attendees of the briefing include: Ms. Zou Jianjun (Executive Director, General Manager and Chief Executive Officer), Mr. Zhang Chun (Independent Non-Executive Director), Mr. Xu Baohong (Financial Director), and Mr. Wang Zhengyu (Secretary of the Board of Directors) (subject to changes in case of any special circumstances).

IV. Ways of Participation by Investors

(I) Investors may access the website of the SSE Roadshow Center (https://roadshow.sseinfo.com/) at 10:00-11:00, 8 September 2025 (Monday) via the internet to participate the briefing online. The Company will respond to the questions of the investors in a timely manner.

(II) Investors are invited to ask the Company questions through the "Pre-collection of Questions" section (https://roadshow.sseinfo.com/preCallQa) at the homepage of the SSE Roadshow Center website by selecting this event according to the event time or send questions to the Company's email (info@junshipharma.com) in advance from 1 September 2025 (Monday) to 16:00, 5 September 2025 (Friday). The Company will respond to questions that are of general concern to investors at the briefing.

V. Contact Details for the Briefing

Contact Department: Securities Department

Contact Tel.: 021-61058800-1153

Contact Email: info@junshipharma.com

VI. Others Matters

Upon the convening of the investor briefing, investors may review the convening details and key contents of the investor briefing at the website of the SSE Roadshow Center (https://roadshow.sseinfo.com/).

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

30 August 2025